Baricitinib

Category: pharmacological

Aliases: Olumiant

Pharmacological Mechanism

JAK1/JAK2 inhibitor — blocks cytokine receptor signaling. Approved for rheumatoid arthritis, atopic dermatitis, alopecia areata, and adjunct in COVID-19 hospitalization. Class effects: infections, MI, malignancy, thrombosis.

Half-Life (t½)

PO: 12h

Dosing Guidelines

• PO: Typical 2mg (Range: 1 - 4 mg)

Target Organ Systems

• cardiovascular
• integumentary
• immune-hematologic